Clinical trial · Interventional
Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer
NCT04110769CI-TRIAL-00059749unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify and apply biomarkers that can provide better information than previous imaging and blood tests when evaluating the response after neoadjuvant chemotherapy in pancreatic cancer patients who require neoadjuvant therapy before surgery.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Effect | — | UNRESOLVED | — |
| Genetic Change | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| following next generation sequencing | Diagnostic Test | — | UNRESOLVED |
| next generation sequencing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Responders
- description
- The investigator will administer neoadjuvant chemotherapy After neoadjuvant chemotherapy, multidisciplinary team will decide to surgery or continuing chemotherapy based on following imaging studies and tumor markers. The patients who undergo surgery after neoadjuvant chemotherapy will be included responders.
- interventionNames
- Diagnostic Test: next generation sequencing
- type
- ACTIVE_COMPARATOR
- label
- Non-responders
- description
- The patients who show cancer progression even after neoadjuvant chemotherapy will be classify with non-responder. And the investigator will change palliative chemotherapy.
- interventionNames
- Diagnostic Test: next generation sequencing
- Diagnostic Test: following next generation sequencing
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * The patients who are going to administer neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic cancer * Performance: 0-2 * No distant metastasis * Patients who consented to and signed the consent Exclusion Criteria: * Distant metastasis * Patients included in other clinical studies that may affect this study * Patients who cannot follow the directions of the researcher * Patients with moderate or severe comorbidities who are thought to have an impact on quality of life or nutritional status (cirrhosis, chronic kidney failure, heart failure, etc.) * Pelvic tumor, benign tumor, malignant tumor in other organs * Patients who received prior chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.